85 results about "Glucose responsive" patented technology

A biocompatible insulin delivery device is provided comprising an insulin reservoir sealed with a glucose-responsive plug or membrane. The plug functions to release insulin from the reservoir in response to a hyperglycemic glucose concentration and to prevent insulin release from the reservoir in response to hypoglycemic glucose concentration. In one embodiment, the plug is made of a biocompatible polymeric matrix comprising an inorganic component, a stimulus-responsive component and a catalytic component.

Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

The invention discloses a 3D printing microneedle patch for intelligent blood glucose regulation and a preparation method thereof, belonging to the biomedical field. The 3D printing microneedle patchof the invention is mainly made of photosensitive material with good biocompatibility, and comprises two parts of a substrate and a microneedle array, wherein the microneedle array comprises a plurality of conical microneedles, and the microneedles contain medicaments for intelligently regulating blood sugar, and the medicaments include carrier materials, glucose-responsive sensitive switching factors and medicaments molecules. The 3D printing microneedle patch of the invention is mainly made of photosensitive material with good biocompatibility. Firstly, the three-dimensional model of micro-needle patch is built by using modeling software, and the model is imported into the printing software of 3D printer. Then the 3D printing technology of photocuring is used to solidify the photosensitive material solution containing photoinitiator and drug according to the structure of the three-dimensional model of the micro-needle patch to obtain the 3D printing micro-needle patch. The microneedle patch of the invention can puncture the skin and intelligently release the loaded insulin according to the blood glucose concentration in the body so as to intelligently regulate the blood glucose level. The invention realizes painless, intelligent and responsive blood glucose regulation.

The invention relates to hydrogel and organogel sensors as well as their application to continuous analyte monitoring. The sensor can include a hydrogel or organogel matrix. Standard and inverse designed are provided. In one embodiment, the matrix can include a molecular recognition agent for an analyte (e.g., a glucose analyte), and a volume resetting agent that reversibly binds with the molecular recognition agent. Reversible crosslinks between the molecular recognition agent and volume resetting agent can change the volume of the matrix upon interacting with the analyte via a competitive binding process. In various embodiments, the invention provides a hydrogel-based glucose sensor and sensors for continuous glucose monitoring. The glucose sensor can be based on a glucose-responsive hydrogel with a volume linearly correlated with glucose concentrations, such as about 0.05-50 mM, under physiological conditions. The invention thus provides a blood glucose monitor suitable for use in clinical settings.

The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and / or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and / or toxicity of potential adjunctive treatment regimes.

The invention relates to a gel material for efficient treatment of tumors and a preparation method thereof. The gel material is composed of a micro organic-inorganic hybrid nano-gel carrier and a bio-enzyme component loaded on the micro organic-inorganic hybrid nano-gel carrier. The micro organic-inorganic hybrid nano-gel carrier comprises an inorganic nanoparticle core and an organic gel layer compounded on the surface of the inorganic nanoparticle core, wherein the organic gel layer is formed by deposition and self-assembly of a gelling factor on the surface of the inorganic nanoparticle core, and the gelling factor is Fmoc- or Nap- functionalized small molecular polypeptide with an aromatic substituent group. Compared with the prior art, the micro organic-inorganic hybrid nano-gel carrier adopted by the invention provides natural protection for loading and immobilization of bio-enzyme, glucose responsive and reactive oxygen species responsive efficient and tandem enzyme-catalyzed reaction is carried out at a tumor site, tumor lesion site or other lesion sites to generate singlet oxygen, thus realizing efficient and safe treatment.

Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

A sterilized food product containing starch, the starch having: (a) an amylose content of at least 60 wt. %; (b) a median particle size of between 1 and 15 &mgr; m, at least 90 wt. % of the starch particles having a particle diameter of less than 50 &mgr; m; and (c) a non-digestible starch content of less than 50 wt. %; and (d) a slowly digestible starch content of 15-75 wt. %. The product is obtained by heating and rapidly cooling the starch product and has a high slowly digestible starch content. It is suitable for use in the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.

The invention provides a preparation method of a controlled release carrier of a glucose-responsive drug, solves insufficiencies that ConA and sugar ligands thereof are needed to be modified in prior art. The method comprises: (1) dissolving sugar-containing polymer units in a lye, adding divinyl sulfone, adjusting a pH to stop reaction, and dialyzing to obtain a sugar-containing polymer with vinyl sulfone groups; (2) dissolving the prepared substances in a buffer solution, adding a ConA activating solution; (3) adjusting pH of the mixture obtained in step (2) by using the buffer solution, adjusting the pH, adding drop by drop the product into a mixed solution of cyclohexane and an emulsion stabilizer, reacting, removing an oil phase at an upper level, and depositing a lower level to obtain the glucose-responsive carrier. By introducing the divinyl sulfone into the ConA-sugar-containing polymer carrier, the preparation steps for the carrier can be simplified, the sugar-containing polymer can be directly crosslinked with the ConA, thereby being simple and high-efficiency to fix the ConA, low in cost, convenient to implement, and beneficial for large-scale production.

The present invention includes compositions and methods for regenerating glucose-responsive cells by ultrasound-targeted microbubble destruction in the pancreas, wherein the composition comprises a pre-assembled liposome-nucleic acid complex in contact with in and about a microbubble, wherein the pre-assembled liposome-nucleic acid complex comprises a NeuroD gene under the control of the promoter, wherein disruption of the microbubble in the pancreas at a target site delivers the nucleic acid into pancreas cells at the location of the ultrasound disruption, wherein cells that incorporate the nucleic acid express insulin in response to high blood glucose levels.

Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

A biocompatible insulin delivery device is provided comprising an insulin reservoir sealed with a glucose-responsive plug or membrane. The plug functions to release insulin from the reservoir in response to a hyperglycemic glucose concentration and to prevent insulin release from the reservoir in response to hypoglycemic glucose concentration. In one embodiment, the plug is made of a biocompatible polymeric matrix comprising an inorganic component, a stimulus-responsive component and a catalytic component.

The invention relates to an orderly porous polymer thin film, a preparation method and application in capture and controllable glucose-responsive release of insulin and belongs to the technical field of controllable release of drugs. The preparation method comprises the following steps of preparing an orderly cellular porous thin film of which the inner wall is loaded with a positively charged surfactant, selectively assembling a glucose-responsive material on the inner walls of pores of the orderly porous thin film, carrying out positioning capture on an insulin aggregate in the pores, carrying out controllable release on the insulin aggregate under the stimulated action of glucose and the like. According to the invention, the device is simple and convenient, the condition is mild, the insulin loading capacity is large, the release efficiency is high, the positioning capture of the insulin aggregate in the pores of the orderly cellular porous thin film can be achieved, and the insulin is efficiently released by virtue of the stimulation of glucose; furthermore, by virtue of changing the concentration of glucose, the regulation on the controllable release behavior of insulin is achieved and a glucose-responsive self-regulating insulin delivery system is established.

Insulin conjugates comprising an insulin analog molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.